How many days should prasugrel be discontinued before elective surgery?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Prasugrel Discontinuation Before Elective Surgery

Discontinue prasugrel 7 days prior to elective surgery. This is the clear recommendation from both the most recent American College of Chest Physicians (ACCP) 2022 guidelines and the FDA drug label 1, 2.

Primary Recommendation

The 2022 ACCP guidelines explicitly state for pre-operative P2Y12 inhibitor interruption: 7 days for prasugrel 1. This aligns perfectly with the FDA boxed warning, which states: "When possible, discontinue prasugrel at least 7 days prior to any surgery" 2.

Context-Specific Considerations

For CABG Surgery

The same 7-day discontinuation window applies specifically to CABG procedures. The ACCP guidelines recommend interrupting P2Y12 inhibitors (including prasugrel) perioperatively for CABG, with the implementation note specifying 7 days for prasugrel 1.

For Patients With Recent Coronary Stents (6-12 weeks)

If your patient has had a coronary stent placed within the last 6-12 weeks, you face a critical decision point. The ACCP guidelines suggest either:

  • Continue both antiplatelet agents through surgery, OR
  • Stop one antiplatelet agent within 7-10 days of surgery 1

This decision hinges on:

  • Timing of stent placement (closer to 6 vs. 12 weeks)
  • Type of stent (drug-eluting vs. bare-metal)
  • Stent location (dominant coronary artery or not)
  • Surgery bleeding risk vs. risk of acute coronary syndrome/stent thrombosis

The Canadian guidelines emphasize a "heart team approach" for these complex decisions 3.

Comparison to Other P2Y12 Inhibitors

For context, prasugrel requires the longest discontinuation period among P2Y12 inhibitors:

  • Prasugrel: 7 days 1
  • Clopidogrel: 5 days 1
  • Ticagrelor: 3-5 days 1

This longer window reflects prasugrel's more potent and sustained platelet inhibition compared to other agents.

Critical Pitfalls to Avoid

Do not start prasugrel in patients likely to undergo urgent CABG 2. This is part of the FDA boxed warning and reflects the significant bleeding risk.

Do not routinely use platelet function testing to guide timing of surgery. The ACCP guidelines recommend against routine platelet function testing prior to surgery, though it could be considered in specific scenarios like CABG in patients who recently started a P2Y12 inhibitor 1.

Do not abruptly discontinue without considering thrombotic risk. The FDA label warns that stopping prasugrel increases the risk of subsequent cardiovascular events 2. Balance this against surgical bleeding risk on a case-by-case basis, particularly in patients with recent stents.

Post-Operative Resumption

Resume prasugrel within 24 hours after surgery when hemostasis is adequate 1. This applies to both general surgery and CABG procedures, though resumption may need to be delayed if post-CABG thrombocytopenia develops (platelet count <50,000/μL) 1.

Special Populations

For patients <60 kg body weight or ≥75 years of age, prasugrel carries additional bleeding risk per the FDA boxed warning 2. The 7-day discontinuation window remains the same, but heightened vigilance for bleeding complications is warranted.

Related Questions

How should dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor such as clopidogrel, prasugrel, or ticagrelor) be managed before and after elective surgery?
When should clopidogrel and prasugrel be discontinued prior to surgery?
Can ketorolac (Toradol) be administered to a patient receiving dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor such as clopidogrel, prasugrel, or ticagrelor)?
What is the recommended cardiac clearance and peri‑operative antiplatelet/anticoagulation management for a patient who had recent percutaneous coronary intervention (angioplasty) and now requires cataract surgery?
Should a patient continue low‑dose aspirin (81 mg) and discontinue clopidogrel (Plavix) before a dental procedure?
In an older adult with aggressive osteoarthritis-like changes and a concerning paraneoplastic history, does diffusely increased intrasubstance signal within a ligament on MRI suggest malignancy?
Is prasugrel appropriate for dual antiplatelet therapy in acute coronary syndrome patients undergoing percutaneous coronary intervention with stent placement who are under 75 years old, weigh at least 60 kg, and have no prior stroke or transient ischemic attack?
Given a blood pressure of 111/42 mmHg, what is the mean arterial pressure (MAP)?
What is the recommended radiation therapy regimen for a spindle‑cell neoplasm that cannot be completely excised or has high‑risk features?
In an older adult with aggressive osteoarthritis-type changes and a known paraneoplastic history, what do reactive adjacent osseous changes represent, and how should they be assessed and managed?
What are the common congenital anomalies of the kidney and urinary tract (CAKUT) associated with secondary pseudohypoaldosteronism?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.